It seems there will never be enough “thank you’s” for the incredible doctors, nurses, technicians and support staff members who are working around the clock to help patients who have the dangerous coronavirus disease. The dedication, determination and spirit enable Johns Hopkins to deliver the promise of medicine.Read more
With the global pandemic and nationwide protests, Americans are more stressed than ever, and strange and vivid dreams are a reality for many.Read more
A novel formulation of the prostate cancer drug abiraterone acetate – currently marketed as Zytiga – will dramatically improve the quality of life for people suffering from prostate cancer, as pre-clinical trials by the University of South Australia show the new formulation improves the drug’s effectiveness by 40 per cent.Read more
Many reports have included pulmonary fibrosis as a potential consequence of COVID-19. Data shows some COVID-19 patients develop scarring on the lungs – but not necessarily chronic pulmonary fibrosis or interstitial lung disease, which are characterized by progressive scarring.Read more
With the ongoing uncertainty of the COVID-19 pandemic and self-isolation, many people are experiencing increased stress. The American Academy of Sleep Medicine (AASM) and Dr. Wickwire provide tips on how to manage anxiety to foster healthy sleep.Read more
Survey results from the American Academy of Sleep Medicine (AASM) find that nearly half of U.S. adults have struggled to stay awake while driving. To help drivers stay alert at the wheel, the AASM offers tips for National Distracted Driving Month in April.Read more
Zinc and folic acid, a pair of dietary supplements long touted as an effective treatment for male infertility, failed to improve pregnancy rates, sperm counts, and sperm potency in a new study conducted at University of Utah Health and other medical centers in conjunction with the National Institutes of Health. According to the researchers, the finding presents the most definitive evidence to date that so-called fertility supplements do not live up expectations.Read more
A new study by Vanderbilt-Ingram Cancer Center (VICC) researchers published in Clinical Cancer Research, a journal of the American Association for Cancer Research, indicates that a lower threshold is needed for male patients to predict mortality using the genetic assay, Oncotype DX®, a commercial diagnostic test. The study’s lead author is Fei Wang, MD, PhD, a visiting research fellow at Vanderbilt University, and its senior author is Xiao-Ou Shu, MD, PhD, MPH, Ingram Professor of Cancer Research and associate director for Global Health and co-leader of the Cancer Epidemiology Research Program at VICC.